keyword
https://read.qxmd.com/read/38604786/-short-term-substitution-of-calcineurin-inhibitors-cni-with-recombinant-humanized-anti-cd25-monoclonal-antibody-basiliximab-as-agvhd-prophylaxis-in-cni-intolerant-patients-after-allogeneic-hematopoietic-stem-cell-transplantation
#21
JOURNAL ARTICLE
S Shao, H X Liu, Y Jiang, S Li, D L Wei, J Zhu, C Wang, C X Zhao
Objectives: To investigate the efficacy of short-term substitution of recombinant humanized anti-CD25 monoclonal antibody (Basiliximab) as acute GVHD (aGVHD) prophylaxis in calcineurin inhibitors (CNI) intolerant patients following allogeneic hematopoietic stem cell transplantation (allo-HSCT) . Methods: This study included 17 patients with refractory malignant hematological disorders who underwent salvage allo-HSCT at the Bone Marrow Transplantation Department of Shanghai Zhaxin Traditional Chinese and Western Medicine Hospital from August 2021 to August 2022 and were treated with Baliximab to prevent aGVHD due to severe adverse reactions to CNI...
February 14, 2024: Zhonghua Xue Ye Xue za Zhi, Zhonghua Xueyexue Zazhi
https://read.qxmd.com/read/38602670/american-radium-society-appropriate-use-criteria-for-unresectable-locally-advanced-non-small-cell-lung-cancer
#22
JOURNAL ARTICLE
George Rodrigues, Kristin A Higgins, Andreas Rimner, Arya Amini, Joe Y Chang, Stephen G Chun, Jessica Donington, Martin J Edelman, Matthew A Gubens, Puneeth Iyengar, Benjamin Movsas, Matthew S Ning, Henry S Park, Andrea Wolf, Charles B Simone
IMPORTANCE: The treatment of locally advanced non-small cell lung cancer (LA-NSCLC) has been informed by more than 5 decades of clinical trials and other relevant literature. However, controversies remain regarding the application of various radiation and systemic therapies in commonly encountered clinical scenarios. OBJECTIVE: To develop case-referenced consensus and evidence-based guidelines to inform clinical practice in unresectable LA-NSCLC. EVIDENCE REVIEW: The American Radium Society (ARS) Appropriate Use Criteria (AUC) Thoracic Committee guideline is an evidence-based consensus document assessing various clinical scenarios associated with LA-NSCLC...
April 11, 2024: JAMA Oncology
https://read.qxmd.com/read/38601443/additional-local-therapy-before-disease-progression-for-egfr-mutated-advanced-lung-cancer-a-systematic-review-and-meta-analysis
#23
JOURNAL ARTICLE
Hayoung Seong, Soo Han Kim, Mi Hyun Kim, Jinmi Kim, Jung Seop Eom
BACKGROUND: International guidelines recommend the use of local therapy (LT) to limited progression in patients with epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer (NSCLC). However, the use of LT before disease progression has not been extensively analyzed. This meta-analysis evaluates the efficacy and safety of administering additional LT in conjunction with first-line EGFR-tyrosine kinase inhibitors (TKIs) before disease progression in patients with EGFR-mutated advanced NSCLC...
March 29, 2024: Translational Lung Cancer Research
https://read.qxmd.com/read/38598832/robotic-salvage-partial-nephrectomy-following-surgical-and-ablative-therapies
#24
Carol L Feng, Antonio Franco, Francesco Ditonno, Celeste Manfredi, Alexander K Chow, Riccardo Autorino
PURPOSE: Partial nephrectomies in the salvage setting after ablative or surgical therapy remain challenging cases that are underreported in the literature (1-5). The aim of this video is to demonstrate techniques for robotic salvage partial nephrectomy to manage recurrent renal cell carcinoma (RCC) after failed prior partial nephrectomy and primary cryotherapy. MATERIALS AND METHODS: A 55-year-old man after previous robotic-assisted right partial nephrectomy presented with a 2...
2024: International Braz J Urol: Official Journal of the Brazilian Society of Urology
https://read.qxmd.com/read/38597202/bruton-s-tyrosine-kinase-btk-inhibitors-for-the-treatment-of-primary-central-nervous-system-lymphoma-pcnsl-current-progress-and-latest-advances
#25
REVIEW
Lauren Schaff, Lakshmi Nayak, Christian Grommes
The incidence of primary central nervous system lymphoma (PCNSL) has steadily increased, particularly in elderly patients. Although highly responsive to first-line chemotherapy and radiotherapy, approximately 50% of patients relapse or become refractory within 1 year. Prognosis following relapse is dismal and no standard salvage therapy exists. Bruton's tyrosine kinase (BTK), a key regulator of the B-cell receptor (BCR) pathway, has emerged as a promising therapeutic target. The first BTK inhibitor ibrutinib has been evaluated in the relapsed/refractory PCNSL setting, with overall response rates of 51...
April 10, 2024: Leukemia & Lymphoma
https://read.qxmd.com/read/38596833/successful-treatment-of-paediatric-refractory-hodgkin-lymphoma-with-immunotherapy-a-case-report-and-literature-review
#26
REVIEW
Nina Mogensen, Carmen Cananau, Susanna Ranta, Jonas Karlén, Anna Kwiecinska, Fredrik Baecklund
AIM: To describe a rare case of primary refractory Hodgkin lymphoma nodular sclerosis syncytial variant in a child and review immunotherapy in relapsed/refractory Hodgkin lymphoma. METHODS: We described the treatment course of a child with primary refractory classic Hodgkin lymphoma and discussed different options for salvage therapy, with an emphasis on immunotherapy. We searched PubMed for all published clinical trials investigating immunotherapy in classic Hodgkin lymphoma written in English until 31 June, 2023...
April 10, 2024: Acta Paediatrica
https://read.qxmd.com/read/38594734/purine-salvage-promotes-treatment-resistance-in-h3k27m-mutant-diffuse-midline-glioma
#27
JOURNAL ARTICLE
Erik R Peterson, Peter Sajjakulnukit, Andrew J Scott, Caleb Heaslip, Anthony Andren, Kari Wilder-Romans, Weihua Zhou, Sravya Palavalasa, Navyateja Korimerla, Angelica Lin, Alexandra O'Brien, Ayesha Kothari, Zitong Zhao, Li Zhang, Meredith A Morgan, Sriram Venneti, Carl Koschmann, Nada Jabado, Costas A Lyssiotis, Maria G Castro, Daniel R Wahl
BACKGROUND: Diffuse midline gliomas (DMG), including diffuse intrinsic pontine gliomas (DIPGs), are a fatal form of brain cancer. These tumors often carry a driver mutation on histone H3 converting lysine 27 to methionine (H3K27M). DMG-H3K27M are characterized by altered metabolism and resistance to standard of care radiation (RT) but how the H3K27M mediates the metabolic response to radiation and consequent treatment resistance is uncertain. METHODS: We performed metabolomics on irradiated and untreated H3K27M isogenic DMG cell lines and observed an H3K27M-specific enrichment for purine synthesis pathways...
April 9, 2024: Cancer & Metabolism
https://read.qxmd.com/read/38593075/removal-of-phosphoglycolate-in-hyperthermophilic-archaea
#28
JOURNAL ARTICLE
Yuta Michimori, Rikihisa Izaki, Yu Su, Yuto Fukuyama, Shigeru Shimamura, Karin Nishimura, Yuya Miwa, Sotaro Hamakita, Takahiro Shimosaka, Yuki Makino, Ryo Takeno, Takaaki Sato, Haruki Beppu, Isaac Cann, Tamotsu Kanai, Takuro Nunoura, Haruyuki Atomi
Many organisms that utilize the Calvin-Benson-Bassham (CBB) cycle for autotrophic growth harbor metabolic pathways to remove and/or salvage 2-phosphoglycolate, the product of the oxygenase activity of ribulose-1,5-bisphosphate carboxylase/oxygenase (Rubisco). It has been presumed that the occurrence of 2-phosphoglycolate salvage is linked to the CBB cycle, and in particular, the C2 pathway to the CBB cycle and oxygenic photosynthesis. Here, we examined 2-phosphoglycolate salvage in the hyperthermophilic archaeon Thermococcus kodakarensis , an obligate anaerobe that harbors a Rubisco that functions in the pentose bisphosphate pathway...
April 16, 2024: Proceedings of the National Academy of Sciences of the United States of America
https://read.qxmd.com/read/38584546/outcomes-of-patients-with-heavily-pretreated-relapsed-refractory-multiple-myeloma-receiving-salvage-cytotoxic-therapy-with-supportive-stem-cell-boost
#29
JOURNAL ARTICLE
Ayrton Bangolo, Samir Oza, Ronit Slotky, Aimee Chappell, David Siegel, Harsh Parmar, Noa Biran, David H Vesole, Pooja Phull
BACKGROUND: Multiple myeloma (MM) is an incurable hematologic malignancy characterized by the neoplastic proliferation of plasma cells, which produce monoclonal immunoglobulin that can cause vital organ damage, subsequently leading to significant morbidity and mortality. Autologous hematopoietic stem cell transplant (ASCT) is the standard-of-care management of eligible patients with newly diagnosed MM. Experts recommend collecting enough stem cells upfront to support a possible tandem transplant, salvage ASCT, or a stem cell "boost" to allow for the administration of multiagent cytotoxic chemotherapy in patients with relapsed/refractory disease...
April 3, 2024: Current Stem Cell Research & Therapy
https://read.qxmd.com/read/38583455/remission-induction-versus-immediate-allogeneic-haematopoietic-stem-cell-transplantation-for-patients-with-relapsed-or-poor-responsive-acute-myeloid-leukaemia-asap-a-randomised-open-label-phase-3-non-inferiority-trial
#30
JOURNAL ARTICLE
Matthias Stelljes, Jan Moritz Middeke, Gesine Bug, Eva-Maria Wagner-Drouet, Lutz P Müller, Christoph Schmid, Stefan W Krause, Wolfgang Bethge, Edgar Jost, Uwe Platzbecker, Stefan A Klein, Jörg Schubert, Judith Niederland, Martin Kaufmann, Kerstin Schäfer-Eckart, Markus Schaich, Henning Baldauf, Friedrich Stölzel, Cathleen Petzold, Christoph Röllig, Nael Alakel, Björn Steffen, Beate Hauptrock, Christoph Schliemann, Katja Sockel, Fabian Lang, Oliver Kriege, Judith Schaffrath, Christian Reicherts, Wolfgang E Berdel, Hubert Serve, Gerhard Ehninger, Alexander H Schmidt, Martin Bornhäuser, Jan-Henrik Mikesch, Johannes Schetelig
BACKGROUND: Whether high-dose cytarabine-based salvage chemotherapy, administered to induce complete remission in patients with poor responsive or relapsed acute myeloid leukaemia scheduled for allogeneic haematopoietic stem-cell transplantation (HSCT) after intensive conditioning confers a survival advantage, is unclear. METHODS: To test salvage chemotherapy before allogeneic HSCT, patients aged between 18 and 75 years with non-favourable-risk acute myeloid leukaemia not in complete remission after first induction or untreated first relapse were randomly assigned 1:1 to remission induction with high-dose cytarabine (3 g/m2 intravenously, 1 g/m2 intravenously for patients >60 years or with a substantial comorbidity) twice daily on days 1-3 plus mitoxantrone (10 mg/m2 intravenously) on days 3-5 or immediate allogeneic HSCT for the disease control group...
April 4, 2024: Lancet Haematology
https://read.qxmd.com/read/38583428/high-dose-chemotherapy-and-autologous-stem-cell-transplantation-for-salvage-therapy-of-relapsed-refractory-germ-cell-tumors-a-single-center-experience
#31
JOURNAL ARTICLE
Gul Sema Yıldıran Keskin, Ismail Ertürk, Musa Baris Aykan, Ramazan Acar, Aysegul Dumludag, Alper Topal, Caglar Koseoglu, Omer Faruk Kuzu, Ece Ornek, Nuri Karadurmus
PURPOSE: The optimal management of relapsed/refractory germ cell tumors remains unsettled. In this study, we aimed to evaluate the efficacy of high-dose chemotherapy (HDCT) and autologous stem cell transplantation (ASCT) as salvage therapy in patients who progressed after at least one line of cisplatin-based chemotherapy. METHODS: We retrospectively reported the results of 133 patients who underwent HDCT and ASCT as salvage therapy from 2016 to 2021. Patients received 3 cycles of paclitaxel, ifosfomide and cisplatin (TIP) regimen as induction and 1 cycle of carboplatin 700 mg/m2 on days 1 to 3 plus etoposide 750 mg/m2 on days 1 to 3, followed by ASCT...
April 5, 2024: Oncology Research and Treatment
https://read.qxmd.com/read/38582841/mir-380-inhibits-the-proliferation-and-invasion-of-cholangiocarcinoma-cells-by-silencing-lis1
#32
JOURNAL ARTICLE
Zhicheng Wei, Bowen Xu, Yanjiang Yin, Jianping Chang, Zhiyu Li, Yefan Zhang, Xu Che, Xinyu Bi
BACKGROUND: The objective of this study was to determine the role and regulatory mechanism of miR-380 in cholangiocarcinoma. METHODS: The TargetScan database and a dual-luciferase reporter assay system were used to determine if LIS1 was a target gene of miR-380. The Cell Counting Kit 8 assay, flow cytometry, and Transwell assay were used to detect the effects of miR-380 and LIS1 on the proliferation, S-phase ratio, and invasiveness of HCCC-9810/HuCCT1/QBC939 cells...
April 6, 2024: Cancer Cell International
https://read.qxmd.com/read/38580495/consensus-of-the-brazilian-association-of-hematology-hemotherapy-and-cellular-therapy-on-patient-blood-management-acute-normovolemic-hemodilution-and-intraoperative-autotransfusion
#33
JOURNAL ARTICLE
Fernanda Vieira Perini, Juan Carlos Montano-Pedroso, Luciana Correa Oliveira, Enis Donizetti, Roseny Dos Reis Rodrigues, Silvia Renata Cornélio Parolin Rizzo, Guilherme Rabello, Dante Mario Langhi Junior
Autologous blood transfusion can be achieved through different techniques, including by the patient donating blood before surgery (pre-deposit), collecting blood from the patient immediately before the operation and replacing the volume with colloids or plasma expanders (acute normovolemic hemodilution) or through the salvage of lost blood, during or immediately after surgery, and its retransfusion after washing (intraoperative or postoperative recovery). We will focus on the two methods used intraoperatively that are of fundamental importance in the management and conservation of the patient's own blood...
March 27, 2024: Hematology, Transfusion and Cell Therapy
https://read.qxmd.com/read/38580317/channeling-nicotinamide-phosphoribosyltransferase-nampt-to-address-life-and-death
#34
REVIEW
Ganga Reddy Velma, Isabella S Krider, Erick T M Alves, Jenna M Courey, Megan S Laham, Gregory R J Thatcher
Nicotinamide phosphoribosyltransferase (NAMPT) catalyzes the rate-limiting step in NAD+ biosynthesis via salvage of NAM formed from catabolism of NAD+ by proteins with NADase activity (e.g., PARPs, SIRTs, CD38). Depletion of NAD+ in aging, neurodegeneration, and metabolic disorders is addressed by NAD+ supplementation. Conversely, NAMPT inhibitors have been developed for cancer therapy: many discovered by phenotypic screening for cancer cell death have low nanomolar potency in cellular models. No NAMPT inhibitor is yet FDA-approved...
April 5, 2024: Journal of Medicinal Chemistry
https://read.qxmd.com/read/38579060/megalosplenia-as-an-initial-manifestation-of-multiple-myeloma-with-a-novel-cyld-gene-mutation-a-case-report-and-literature-review
#35
JOURNAL ARTICLE
Jinjing Zhang, Rui Zhang
INTRODUCTION: Megalosplenia in newly diagnosed multiple myeloma (MM) is extremely rare, posing diagnostic and therapeutic challenges due to its unusual location and clinical manifestations and lack of optimal therapeutic strategies. CASE PRESENTATION: A 65-year-old female who was previously healthy presented with a history of ecchymosis on her right leg accompanied by progressive fatigue for 2 weeks. She was admitted to our center in July 2019 due to thrombocytopenia...
April 5, 2024: Medicine (Baltimore)
https://read.qxmd.com/read/38576387/diagnostic-challenges-and-emerging-pathogeneses-of-selected-glomerulopathies
#36
JOURNAL ARTICLE
Nicole K Andeen, Jean Hou
Recent progress in glomerular immune complex and complement-mediated diseases have refined diagnostic categories and informed mechanistic understanding of disease development in pediatric patients. Herein, we discuss selected advances in 3 categories. First, membranous nephropathy antigens are increasingly utilized to characterize disease in pediatric patients and include phospholipase A2 receptor (PLA2R), Semaphorin 3B (Sema3B), neural epidermal growth factor-like 1 (NELL1), and protocadherin FAT1, as well as the lupus membranous-associated antigens exostosin 1/2 (EXT1/2), neural cell adhesion molecule 1 (NCAM1), and transforming growth factor beta receptor 3 (TGFBR3)...
April 5, 2024: Pediatric and Developmental Pathology
https://read.qxmd.com/read/38574855/evidence-based-cesarean-delivery-preoperative-management-part-7
#37
REVIEW
A Dhanya Mackeen, Maranda V Sullivan, Vincenzo Berghella
The preoperative preparation for cesarean delivery is a multistep approach for which protocols should exist at each hospital system. These protocols should be guided by the findings of this review. The interventions reviewed and recommendations made for this review have a common goal of decreasing maternal and neonatal morbidity and mortality related to cesarean delivery (CD). The preoperative time period starts prior to the patient's arrival to the hospital and ends immediately prior to skin incision. Skin cleansing in addition to CDC recommendations of showering with either soap or an antiseptic solution at least the night prior to a procedure has not been shown to further decrease rates of infection...
April 2, 2024: American journal of obstetrics & gynecology MFM
https://read.qxmd.com/read/38565964/salvage-haploidentical-transplantation-for-graft-failure-after-first-haploidentical-allogeneic-stem-cell-transplantation-an-updated-experience
#38
JOURNAL ARTICLE
Rui Ma, Dan-Ping Zhu, Xiao-Hui Zhang, Lan-Ping Xu, Yu Wang, Xiao-Dong Mo, Meng Lv, Yuan-Yuan Zhang, Yi-Fei Cheng, Chen-Hua Yan, Yu-Hong Chen, Yao Chen, Jing-Zhi Wang, Feng-Rong Wang, Ting-Ting Han, Jun Kong, Zhi-Dong Wang, Wei Han, Huan Chen, Ying-Jun Chang, Yun He, Zheng-Li Xu, Feng-Mei Zheng, Hai-Xia Fu, Kai-Yan Liu, Xiao-Jun Huang, Yu-Qian Sun
Graft failure is a fatal complication following allogeneic stem cell transplantation where a second transplantation is usually required for salvage. However, there are no recommended regimens for second transplantations for graft failure, especially in the haploidentical transplant setting. We recently reported encouraging outcomes using a novel method (haploidentical transplantation from a different donor after conditioning with fludarabine and cyclophosphamide). Herein, we report updated outcomes in 30 patients using this method...
April 2, 2024: Bone Marrow Transplantation
https://read.qxmd.com/read/38565429/targeting-nad-metabolism-pre-clinical-insights-into-potential-cancer-therapy-strategies
#39
JOURNAL ARTICLE
Ayça N Mogol, Alanna Z Kaminsky, David J Dutton, Zeynep Madak Erdogan
NAD+ is one of the most important metabolites for cellular activities, and its biosynthesis mainly occurs through the salvage pathway using the NAMPT enzyme. The main NAD consumers, PARP and SIRT enzymes, are heavily involved in DNA repair and chromatin remodeling. Since cancer cells shift their energy production pathway, NAD levels are significantly affected. NAD's roles in cell survival led to the use of NAD depletion in cancer therapies. NAMPT inhibition (alone or in combination with other cancer therapies, including endocrine therapy and chemotherapy) results in decreased cell viability and tumor burden for many cancer types...
April 3, 2024: Endocrinology
https://read.qxmd.com/read/38563345/sequence-not-salvage
#40
JOURNAL ARTICLE
Douglas W Sborov, Gliceida Galarza Fortuna, Patrick J Hayden
Chimeric antigen receptor T-cell (CAR-T) therapy for the treatment of multiple myeloma (MM) has fundamentally changed the relapsed and refractory therapeutic landscape, but the disease remains incurable. Two CAR-T products, idecabtagene vicleucel (ide-cel; Abecma) and ciltacabtagene autoleucel (cilta-cel, Carvykti), have been FDA- and EMA-approved for the treatment of relapsed/refractory MM (RRMM); both target B-cell maturation antigen (BCMA), a surface glycoprotein highly expressed on MM cells. Despite deep and durable responses following CAR-T therapy, most patients will need subsequent treatment, and the optimal next-line therapy is presently unclear...
April 2, 2024: British Journal of Haematology
keyword
keyword
95772
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.